首页> 外文期刊>Journal of Surgical Oncology >Summary outcomes of two-stage resection for advanced colorectal liver metastases
【24h】

Summary outcomes of two-stage resection for advanced colorectal liver metastases

机译:晚期大肠肝转移的两阶段切除的总结结果

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background: Surgical resection is associated with improved long-term survival in patients with colorectal liver metastases (CLM). However, majority of patients have unresectable bilobar advanced liver metastases. Two-stage resection (TSR) allows selected patients to achieve complete resection when combined with chemotherapy and interventional radiological procedures. Methods: Electronic search of the MEDLINE and PubMed databases (January 2000-October 2011) to identify studies examining the outcomes of the surgical approach of TSR of advanced CLM was undertaken. Results: Twelve studies were examined. This comprised 488 patients. A median of 77% (range: 64-100%) of planned patients completed TSR. The most common reason for failure was due to disease progression observed in a median of 100% (range: 56-100%) of patients. Second-stage resection appeared to be more morbid compared to first-stage resection with higher complication rates (33% vs. 14%) and requiring more blood transfusions (3 U vs. 1 U). Completed TSR achieved a median survival of 37 (range: 18-66) months, median 3-year survival rate of 60% (range: 45-84%), and median 5-year survival rate of 48% (range: 32-70%). In patients who failed TSR, the median survival was 16 (range: 10-29) months. Conclusion In carefully selected candidates with advanced bilobar CLM, the TSR approach achieves long-term survival in patients who would otherwise be considered for palliative chemotherapy only. Despite failing to complete TSR, patients had an encouraging survival outcome that appeared to compare favorably over palliative chemotherapy alone.
机译:背景:外科切除术可改善结直肠肝转移(CLM)患者的长期生存率。但是,大多数患者有无法切除的胆总管晚期肝转移。两阶段切除术(TSR)使选定的患者与化学疗法和介入放射学程序相结合即可实现完全切除。方法:对MEDLINE和PubMed数据库(2000年1月至2011年10月)进行电子搜索,以鉴定研究晚期CLM的TSR手术方法结果的研究。结果:检查了十二项研究。这包括488名患者。计划中的患者中有77%(范围:64-100%)完成了TSR。失败的最常见原因是由于中位100%(范围:56-100%)的患者观察到疾病进展。与第一阶段切除术相比,第二阶段切除术的病态性更高,并发症发生率更高(33%比14%),并且需要更多的输血(3 U比1 U)。完成的TSR的中位生存期为37(范围:18-66)个月,中位3年生存率是60%(范围:45-84%),中位5年生存率是48%(范围:32- 70%)。在TSR失败的患者中,中位生存期为16(范围:10-29)个月。结论在精心挑选的晚期双叶CLM患者中,TSR方法可在原本仅考虑姑息化疗的患者中实现长期生存。尽管未能完成TSR,但患者的生存结局令人鼓舞,似乎比单纯的姑息性化疗要好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号